Skip to main content

Home/ Cerebral Palsy/ Group items matching "Rabeprazole" in title, tags, annotations or url

Group items matching
in title, tags, annotations or url

Sort By: Relevance | Date Filter: All | Bookmarks | Topics Simple Middle
Lee Vander Loop

Effect of Rabeprazole and Lansoprazole on Reflux Esophagitis in Relation to CYP2C19 Genotype Status - 0 views

www.clinicaltrials.gov/...NCT01008696

reflux esophagitis study GERD lansoprazole esophagitis

shared by Lee Vander Loop on 14 May 10 - Cached
  • Lee Vander Loop on 14 May 10
     
    Completed clinical study compared the treatment effects of rabeprazole and lansoprazole depending on the genetic constitution of a enzyme in the liver in treating reflux esophagitis and the cure rate on endoscopy after treatment with rabeprazole 20 mg or lansoprazole 30 mg once daily for 4 to 8 weeks.
Lee Vander Loop

A Pharmacokinetics (Blood Levels), Pharmacodynamics (How the Drug Acts on the Body) and Safety Study Dosing of Rabeprazole in New Borns With Gastroesophageal Reflux Disease (GERD) - 0 views

www.clinicaltrials.gov/...NCT00855361

gastroesophageal reflux disease gastroesophageal reflux antacids and neonates clinical trials safety reflux GERD antacids PPI pharmacokinetics Rabeprazole

shared by Lee Vander Loop on 06 May 10 - Cached
  • Lee Vander Loop on 06 May 10
     
    Study is to evaluate the pharmacokinetics (blood levels), pharmacodynamics (how the drug acts on the body), and the safety of rabeprazole sodium for the treatment of gastroesophageal reflux disease (GERD) in new borns and pre-term infants (less than 44 weeks of age).
Lee Vander Loop

To Evaluate the Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD) - 0 views

www.clinicaltrials.gov/...NCT00992589

gastroesophageal reflux clinical trial clinical trials gastroesophageal reflux disease protein pump inhibitor reflux GERD study Rabeprazole PPI

shared by Lee Vander Loop on 06 May 10 - Cached
  • Lee Vander Loop on 06 May 10
     
    Purpose of this study is to assess the effectiveness and safety of rabeprazole sodium, an inhibitor of gastric acid secretion of the protein pump inhibitor (PPI) class, compared with placebo in the treatment of gastrointestinal esophageal reflux disease (GERD) in infants 1 to 11 months of age.
1 - 3 of 3
Showing 20▼ items per page